Overview
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.
Eligibility
Inclusion Criteria:
- Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria.
- No evidence of extrahepatic metastasis, regional lymph node involvement, or vascular tumor thrombus.
- Patients must be eligible for TAE or TACE treatment.
- ECOG ≤ 1.
- Child-Pugh score ≤ 7.
- Adequate bone marrow, liver, and kidney function is required.
Exclusion Criteria:
- History of liver transplantation.
- Previous radioemblization or radiotherapy for liver tumors.
- severe cardiovascular or renal diseases, active systemic infections.
- Clinically significant hypoxia (oxygen saturation \< 92% without oxygen supplementation)
